Update: Merck’s Patritumab Deruxtecan Outperforms Doublet Chemotherapy
Merck & Co. announced that Patritumab Deruxtecan showed significant progress in patients with advanced EGFR-mutated lung cancer in a Phase 3 trial. For more information, visit the company’s website.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
